{"id":62738,"date":"2026-04-09T20:49:14","date_gmt":"2026-04-09T12:49:14","guid":{"rendered":"https:\/\/flcube.com\/?p=62738"},"modified":"2026-04-09T20:49:15","modified_gmt":"2026-04-09T12:49:15","slug":"luye-pharma-doses-first-patient-in-phase-ii-study-of-ly03020-worlds-first-dual-target-taar1-5-ht2cr-agonist-for-schizophrenia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62738","title":{"rendered":"Luye Pharma Doses First Patient in Phase II Study of LY03020 \u2013 World&#8217;s First Dual\u2011Target TAAR1\/5\u2011HT2CR Agonist for Schizophrenia"},"content":{"rendered":"\n<p><strong>Luye Pharma Group<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2186:HKG\">HKG:\u202f2186<\/a>) announced <strong>first patient enrollment<\/strong> in a <strong>Phase II clinical study<\/strong> evaluating <strong>LY03020<\/strong>, the <strong>world&#8217;s first dual\u2011target agonist<\/strong> of <strong>trace amine\u2011associated receptor 1 (TAAR1)<\/strong> and <strong>serotonin 2C receptor (5\u2011HT2CR)<\/strong>, for the treatment of <strong>acute schizophrenia<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-design\">Clinical Trial Design<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase<\/strong><\/td><td>Phase II<\/td><\/tr><tr><td><strong>Design<\/strong><\/td><td>Multicenter, randomized, double\u2011blind, parallel\u2011group, placebo\u2011controlled, fixed\u2011dose<\/td><\/tr><tr><td><strong>Location<\/strong><\/td><td>China<\/td><\/tr><tr><td><strong>Primary Objectives<\/strong><\/td><td>Efficacy, safety, pharmacokinetics in acute schizophrenia<\/td><\/tr><tr><td><strong>Secondary Objectives<\/strong><\/td><td>Effective dose range exploration<\/td><\/tr><tr><td><strong>First Patient Dosed<\/strong><\/td><td>April\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>LY03020<\/strong> \u2013 First\u2011in\u2011class <strong>dual\u2011target agonist<\/strong><\/li>\n\n\n\n<li><strong>Targets:<\/strong><\/li>\n\n\n\n<li><strong>TAAR1<\/strong> (trace amine\u2011associated receptor 1) \u2013 Modulates dopaminergic, glutamatergic, and serotonergic neurotransmission<\/li>\n\n\n\n<li><strong>5\u2011HT2CR<\/strong> (serotonin 2C receptor) \u2013 Regulates mood, appetite, and psychosis<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Simultaneous activation of TAAR1 and 5\u2011HT2CR offers <strong>synergistic antipsychotic effects<\/strong> with potentially improved metabolic profile vs. conventional D2 antagonists<\/li>\n\n\n\n<li><strong>Indications Under Development:<\/strong><\/li>\n\n\n\n<li>Schizophrenia (lead indication)<\/li>\n\n\n\n<li>Psychotic disorder in Alzheimer&#8217;s disease<\/li>\n\n\n\n<li>Bipolar disorder<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-development-status\">Global Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Regulatory Status<\/th><th>Milestone<\/th><\/tr><\/thead><tbody><tr><td><strong>China<\/strong><\/td><td>Phase II ongoing<\/td><td>First patient dosed Apr\u202f2026<\/td><\/tr><tr><td><strong>United States<\/strong><\/td><td>IND approved<\/td><td>Cleared for clinical trials<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>LY03020 represents Luye Pharma&#8217;s <strong>parallel China\u2011US development strategy<\/strong> for CNS therapeutics, following the company&#8217;s established track record in innovative neuropsychiatric drug development.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Schizophrenia Market:<\/strong> Global market valued at <strong>US$8\u201110\u202fbillion<\/strong> annually; dominated by generic atypical antipsychotics with significant unmet need for therapies addressing <strong>negative symptoms and cognitive impairment<\/strong> without metabolic side effects.<\/li>\n\n\n\n<li><strong>TAAR1 Competitive Landscape:<\/strong><\/li>\n\n\n\n<li><strong>Sunovion \/ Sumitomo<\/strong> \u2013 Ulotaront (TAAR1 agonist) in Phase III<\/li>\n\n\n\n<li><strong>Roche<\/strong> \u2013 Ralmitaront (TAAR1 partial agonist) in Phase II<\/li>\n\n\n\n<li><strong>Luye Pharma<\/strong> \u2013 <strong>LY03020 (dual TAAR1\/5\u2011HT2CR)<\/strong> \u2013 Only dual\u2011mechanism asset in clinic<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Dual\u2011target approach may deliver <strong>superior efficacy on negative symptoms<\/strong> and <strong>reduced weight gain liability<\/strong> compared to selective TAAR1 agonists and D2 blockers.<\/li>\n\n\n\n<li><strong>CNS Pipeline Value:<\/strong> Successful Phase II readout (expected <strong>2027\u20112028<\/strong>) could support <strong>US$500\u202fmillion\u20111\u202fbillion<\/strong> partnership valuation; Luye retains full global rights.<\/li>\n\n\n\n<li><strong>Expansion Potential:<\/strong> Alzheimer&#8217;s disease psychosis represents <strong>additional US$2\u20113\u202fbillion<\/strong> addressable market with no approved therapies.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical trial outcomes, regulatory pathways, and commercial prospects for LY03020. Actual results may differ due to risks including efficacy failures, safety signals, patient enrollment delays, and competitive advances in the TAAR1 class.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040802699_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026040802699_c.\"><\/object><a id=\"wp-block-file--media-41aad942-80ee-4778-8524-76bc544f1dfb\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040802699_c.pdf\">2026040802699_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040802699_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-41aad942-80ee-4778-8524-76bc544f1dfb\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Luye Pharma Group (HKG:\u202f2186) announced first patient enrollment in a Phase II clinical study evaluating&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,1023,219],"class_list":["post-62738","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-2186","tag-luye-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Luye Pharma Doses First Patient in Phase II Study of LY03020 \u2013 World&#039;s First Dual\u2011Target TAAR1\/5\u2011HT2CR Agonist for Schizophrenia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Luye Pharma Group (HKG:\u202f2186) announced first patient enrollment in a Phase II clinical study evaluating LY03020, the world&#039;s first dual\u2011target agonist of trace amine\u2011associated receptor 1 (TAAR1) and serotonin 2C receptor (5\u2011HT2CR), for the treatment of acute schizophrenia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62738\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Luye Pharma Doses First Patient in Phase II Study of LY03020 \u2013 World&#039;s First Dual\u2011Target TAAR1\/5\u2011HT2CR Agonist for Schizophrenia\" \/>\n<meta property=\"og:description\" content=\"Luye Pharma Group (HKG:\u202f2186) announced first patient enrollment in a Phase II clinical study evaluating LY03020, the world&#039;s first dual\u2011target agonist of trace amine\u2011associated receptor 1 (TAAR1) and serotonin 2C receptor (5\u2011HT2CR), for the treatment of acute schizophrenia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62738\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-09T12:49:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-09T12:49:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62738#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62738\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Luye Pharma Doses First Patient in Phase II Study of LY03020 \u2013 World&#8217;s First Dual\u2011Target TAAR1\\\/5\u2011HT2CR Agonist for Schizophrenia\",\"datePublished\":\"2026-04-09T12:49:14+00:00\",\"dateModified\":\"2026-04-09T12:49:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62738\"},\"wordCount\":395,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 2186\",\"Luye Pharma\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62738#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62738\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62738\",\"name\":\"Luye Pharma Doses First Patient in Phase II Study of LY03020 \u2013 World's First Dual\u2011Target TAAR1\\\/5\u2011HT2CR Agonist for Schizophrenia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-09T12:49:14+00:00\",\"dateModified\":\"2026-04-09T12:49:15+00:00\",\"description\":\"Luye Pharma Group (HKG:\u202f2186) announced first patient enrollment in a Phase II clinical study evaluating LY03020, the world's first dual\u2011target agonist of trace amine\u2011associated receptor 1 (TAAR1) and serotonin 2C receptor (5\u2011HT2CR), for the treatment of acute schizophrenia.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62738#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62738\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62738#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Luye Pharma Doses First Patient in Phase II Study of LY03020 \u2013 World&#8217;s First Dual\u2011Target TAAR1\\\/5\u2011HT2CR Agonist for Schizophrenia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Luye Pharma Doses First Patient in Phase II Study of LY03020 \u2013 World's First Dual\u2011Target TAAR1\/5\u2011HT2CR Agonist for Schizophrenia - Insight, China&#039;s Pharmaceutical Industry","description":"Luye Pharma Group (HKG:\u202f2186) announced first patient enrollment in a Phase II clinical study evaluating LY03020, the world's first dual\u2011target agonist of trace amine\u2011associated receptor 1 (TAAR1) and serotonin 2C receptor (5\u2011HT2CR), for the treatment of acute schizophrenia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62738","og_locale":"en_US","og_type":"article","og_title":"Luye Pharma Doses First Patient in Phase II Study of LY03020 \u2013 World's First Dual\u2011Target TAAR1\/5\u2011HT2CR Agonist for Schizophrenia","og_description":"Luye Pharma Group (HKG:\u202f2186) announced first patient enrollment in a Phase II clinical study evaluating LY03020, the world's first dual\u2011target agonist of trace amine\u2011associated receptor 1 (TAAR1) and serotonin 2C receptor (5\u2011HT2CR), for the treatment of acute schizophrenia.","og_url":"https:\/\/flcube.com\/?p=62738","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-09T12:49:14+00:00","article_modified_time":"2026-04-09T12:49:15+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62738#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62738"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Luye Pharma Doses First Patient in Phase II Study of LY03020 \u2013 World&#8217;s First Dual\u2011Target TAAR1\/5\u2011HT2CR Agonist for Schizophrenia","datePublished":"2026-04-09T12:49:14+00:00","dateModified":"2026-04-09T12:49:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62738"},"wordCount":395,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","HKG: 2186","Luye Pharma"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62738#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62738","url":"https:\/\/flcube.com\/?p=62738","name":"Luye Pharma Doses First Patient in Phase II Study of LY03020 \u2013 World's First Dual\u2011Target TAAR1\/5\u2011HT2CR Agonist for Schizophrenia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-09T12:49:14+00:00","dateModified":"2026-04-09T12:49:15+00:00","description":"Luye Pharma Group (HKG:\u202f2186) announced first patient enrollment in a Phase II clinical study evaluating LY03020, the world's first dual\u2011target agonist of trace amine\u2011associated receptor 1 (TAAR1) and serotonin 2C receptor (5\u2011HT2CR), for the treatment of acute schizophrenia.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62738#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62738"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62738#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Luye Pharma Doses First Patient in Phase II Study of LY03020 \u2013 World&#8217;s First Dual\u2011Target TAAR1\/5\u2011HT2CR Agonist for Schizophrenia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62738"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62738\/revisions"}],"predecessor-version":[{"id":62740,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62738\/revisions\/62740"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62738"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62738"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}